Summary
In a 33-year-old patient with severe primary pulmonary hypertension, the acute administration of the angiotensin-converting-enzyme inhibitor captopril (SQ 14, 225) The patient was treated with bed rest, frusemide (40 mg/day) and amiloride (5 mg twice/day). Chest X-ray showed cardiomegaly with a large right ventricle and oligaemic lung fields. Haemoglobin was 14-9 g/dl with normal white cell and platelet counts. Arterial blood gases (while breathing air) were Po2, 35; Pco2, 34; In view of the patient's deteriorating clinical status, a trial of captopril (SQ 14,225) was arranged. Informed consent was obtained, and treatment with indomethacin (125 mg/day) was commenced before the initiation of treatment with captopril.
A Swan-Ganz thermodilution catheter was inserted for monitoring of the haemodynamic effects before and after the initial dose of captopril (6 mg). These are summarized in Table 1 (Sleeper, Orgain and McIntosh, 1962) , recent studies of the vasodilator drugs such as hydrallazine (Rubin and Peter, 1980) , phentolamine (Ruskin and Hutter, 1979) and diazoxide (Wang et al., 1978) , raise hopes that the course of the disease may be significantly altered (Reeves, 1980) .
A number of studies suggested that captopril and other angiotensin-converting-enzyme inhibitors might be particularly effective in reducing elevated pulmonary vascular resistance. Teprotide (SQ 20,881), a related drug, has been shown to produce a fall in pulmonary vascular resistance which is more marked than its effects on systemic vascular resistance in patients with hypertension (Niarchos, Roberts and Laragh, 1979) and congestive cardiac failure (Curtiss et al., 1978) . Whether this effect is primarily due to inhibition of angiotensin II formation, decreased inactivation of plasma kinins, or secondary changes in the formation of vasodilator prostaglandins and prostacyclin, remains to be determined.
The present report is the first one of the use of captopril for this clinical condition. The patient was unfortunately in a moribund state at the start of the study, with clinical evidence of gross right heart failure associated with gross depression of cardiac output. Captopril was made available on the condition that the patient be pre-treated with indomethacin, because of fears of a possible bronchoconstrictor effect mediated by kinin and prostaglandin release (Greenberg et al., 1979) . However, it is also possible that the pulmonary vasodilator effects of captopril which might be mediated by prostacyclin release, were significantly attentuated by indomethacin (Murthy, Waldron and Goldberg, 1978 
